Home    Back

Vib4920    (DrugBank: -)

2 diseases
IDDisease name (Link within this page)Number of trials
46Malignant rheumatoid arthritis2
53Sjogren syndrome4

46. Malignant rheumatoid arthritis    [ 4,183 clinical trials,   2,538 drugs,   (DrugBank: 401 drugs),   183 drug target genes,   219 drug target pathways]
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 4,183 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04163991
(ClinicalTrials.gov)		December 9, 201912/11/2019A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid ArthritisA Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of VIB4920 in Patients With Rheumatoid Arthritis (RA)Rheumatoid ArthritisDrug: VIB4920;Drug: PlaceboViela BioNULLRecruiting18 Years99 YearsAll75Phase 2United States;Poland
2NCT02780388
(ClinicalTrials.gov)		May 12, 20163/5/2016A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid ArthritisA Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid ArthritisAdult Onset Rheumatoid ArthritisDrug: VIB4920;Other: PlaceboViela BioNULLCompleted18 Years70 YearsAll57Phase 1United States;Poland

53. Sjogren syndrome    [ 234 clinical trials,   270 drugs,   (DrugBank: 85 drugs),   49 drug target genes,   174 drug target pathways]
Searched query = "Sjogren syndrome", "Sjögren syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 234 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2019-002713-19-HU
(EUCTR)		30/12/202002/11/2020A study to look at the effectiveness and safety of test product VIB4920 in subjects with Sjögren’s Syndrome (SS)A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects with Sjögren’s Syndrome (SS) Sjögren's syndrome
MedDRA version: 21.1;Level: LLT;Classification code 10059142;Term: Sjoegren's syndrome;System Organ Class: 100000004859;Therapeutic area: Body processes [G] - Immune system processes [G12]		Product Name: VIB4920
INN or Proposed INN: Not applicable
Other descriptive name: MEDI4920		Viela Bio, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		174Phase 2United States;Taiwan;Italy;United Kingdom;India;France;Hungary;Mexico;Argentina;Poland;Peru;China;Korea, Republic of
2EUCTR2019-002713-19-PL
(EUCTR)		26/02/202022/11/2019A study to look at the effectiveness and safety of test product VIB4920 in subjects with Sjögren’s Syndrome (SS)A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in subjects with Sjögren’s Syndrome (SS) Sjögren's syndrome
MedDRA version: 21.1;Level: LLT;Classification code 10059142;Term: Sjoegren's syndrome;System Organ Class: 100000004859 ;Therapeutic area: Body processes [G] - Immune system processes [G12]		Viela Bio, Inc.NULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes		174Phase 2United States;Greece;Spain;Turkey;United Kingdom;Italy;India;France;Mexico;Argentina;Poland;Peru;China;Korea, Republic of
3EUCTR2019-002713-19-GB
(EUCTR)		15/01/202021/11/2019A study to look at the effectiveness and safety of test product VIB4920 in subjects with Sjögren’s Syndrome (SS)A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in subjects with Sjögren’s Syndrome (SS) Sjögren's syndrome
MedDRA version: 21.1;Level: LLT;Classification code 10059142;Term: Sjoegren's syndrome;System Organ Class: 100000004859;Therapeutic area: Body processes [G] - Immune system processes [G12]		Product Name: VIB4920
INN or Proposed INN: Not applicable
Other descriptive name: MEDI4920		Viela Bio, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		174Phase 2China;Korea, Republic of;United States;Greece;Turkey;United Kingdom;Italy;India;France;Mexico;Argentina;Poland;Peru
4NCT04129164
(ClinicalTrials.gov)		October 16, 20192/10/2019A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's SyndromeA Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects With Sjögren's Syndrome (SS)Sjögren's SyndromeDrug: VIB4920;Drug: PlaceboViela BioNULLRecruiting18 Years75 YearsAll174Phase 2United States;Korea, Republic of;Poland;United Kingdom

Back to top